Rasio utang marang kapitalisasi buku: Caribou Biosciences (CRBU)

Risks for Caribou Biosciences (CRBU) are linked to patent conflicts and the danger of off-target mutations amid multi-billion dollar expenditures. This chart on the GURU.Markets platform reflects the asset's price action, with a value of 0.27. Development is conducted in the US, providing immunity to sanctions. Business success relies on the approval of gene-editing methods and the results of lymphoma therapy trials.

This indicator measures the proportion of borrowed funds within the total capital structure, determining the degree of financial leverage and the risk of insolvency at a value of 0.27. By analyzing the debt-to-capitalization ratio, an investor assesses the ability of Caribou Biosciences (CRBU) to fund CRISPR research through strategic alliances, where a low debt load minimizes risks when implementing long-term cell therapy programs.